547
Participants
Start Date
September 30, 2010
Primary Completion Date
June 30, 2012
Study Completion Date
June 30, 2012
Placebo (low dose)
Placebo tablets once a day
Placebo (low dose)
Placebo tablets once a day
Placebo (mid dose)
Placebo tablets once a day
Placebo (high dose)
Placebo tablets once a day
BI 10773
BI 10773 tablets low dose once a day
Placebo (mid dose)
Placebo tablets once a day
Placebo (high dose)
Placebo tablets once a day
Placebo (high dose)
Placebo tablets once a day
BI 10773
BI 10773 tablets mid-high dose once a day
BI 10773
BI 10773 tablets high dose once a day
Placebo (mid dose)
Placebo tablets once a day
Placebo (high dose)
Placebo tablets once a day
Placebo (low dose)
Placebo tablets once a day
Placebo (low dose)
Placebo tablets once a day
BI 10773
BI 10773 tablets mid-low dose once a day
Placebo (mid dose)
Placebo tablets once a day
1245.38.016 Boehringer Ingelheim Investigational Site, Chiyoda-ku, Tokyo
1245.38.001 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo
1245.38.003 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo
1245.38.002 Boehringer Ingelheim Investigational Site, Hachioji, Tokyo
1245.38.010 Boehringer Ingelheim Investigational Site, Hanamaki, Iwate
1245.38.005 Boehringer Ingelheim Investigational Site, Kamakura, Kanagawa
1245.38.020 Boehringer Ingelheim Investigational Site, Kanazawa, Ishikawa
1245.38.013 Boehringer Ingelheim Investigational Site, Kashiwa, Chiba
1245.38.019 Boehringer Ingelheim Investigational Site, Katsushika-ku, Tokyo
1245.38.021 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto
1245.38.024 Boehringer Ingelheim Investigational Site, Matsuyama, Ehime
1245.38.004 Boehringer Ingelheim Investigational Site, Minato-ku, Tokyo
1245.38.011 Boehringer Ingelheim Investigational Site, Moriya, Ibaraki
1245.38.030 Boehringer Ingelheim Investigational Site, Naha, Okinawa
1245.38.032 Boehringer Ingelheim Investigational Site, Okawa, Fukuoka
1245.38.031 Boehringer Ingelheim Investigational Site, Okinawa, Okinawa
1245.38.025 Boehringer Ingelheim Investigational Site, Saga, Saga
1245.38.014 Boehringer Ingelheim Investigational Site, Saitama, Saitama
1245.38.006 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido
1245.38.007 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido
1245.38.008 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido
1245.38.009 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido
1245.38.012 Boehringer Ingelheim Investigational Site, Sasima-gun, Ibaraki
1245.38.015 Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo
1245.38.018 Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo
1245.38.017 Boehringer Ingelheim Investigational Site, Suginami-ku, Tokyo
1245.38.022 Boehringer Ingelheim Investigational Site, Suita, Osaka
1245.38.023 Boehringer Ingelheim Investigational Site, Ube, Yamaguchi
1245.38.026 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa
1245.38.027 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa
1245.38.028 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa
1245.38.029 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa
Lead Sponsor
Eli Lilly and Company
INDUSTRY
Boehringer Ingelheim
INDUSTRY